Key result
VTE in cancer patients predicts up to ~8-fold higher mortality.
Why the study?
Hypercoagulation and venous thromboembolism are frequent and increasingly common complications in malignancy, with important implications for lung cancer prognosis and treatment.
Hypercoagulation and venous thromboembolism are significant complications in lung cancer that negatively impact patient prognosis and mortality.
TF activation may link VTE to tumor progression in cancer; hypothesis-generating and leaves open therapeutic implications.
Hypercoagulation with a clinical manifestation of Venous Thromboembolism (VTE) is a frequent complication of malignancy whose incidence has increased markedly these recent years. The occurrence of VTE is likely to be triggered by multiple pathways dominated by tissue factor (TF). The VTE itself can directly lead to patient mortality and becoming the cause of death in cancer patients. Furthermore, emerging data suggest that activation of coagulation in malignancy is integrally linked with tumor biology, host associated and cancer treatment particularly with anti-angiogenesis. The clinical hypercoagulable state is linked with prognosis in patients with lung cancer, including patients receiving systemic chemotherapy. (J Respir Indo 2019; 39(2): 130-9)
No takes yet. Share an insight, caveat, or question.
Harlivasari et al. (2019) conducted a review in Lung Cancer and Hypercoagulation. Hypercoagulation / Venous Thromboembolism was evaluated. Venous thromboembolism in cancer patients serves as a negative predictive factor for survival and increases mortality by 2 to 8 times.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: